Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
Immune-related adverse events
immunotherapy
melanoma
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
epublish
Résumé
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE). Currently, the toxicity of irAE is limiting the usage of ICIs. Here, we studied circulating monocytic myeloid-derived suppressor cells (M-MDSCs) and T cells in course of irAE after the ICI therapy. Our longitudinal study involved 31 melanoma patients with and without adverse events during anti-PD-1 monotherapy or anti-CTLA-4/PD-1 combination therapy. Peripheral blood samples were analyzed before ICI start, during ICI treatment, at the time point of irAE and during immunosuppressive treatment to cure irAE. We observed an enhanced progression-free survival among patients with irAE. In patients with irAE, we found an upregulation of CD69 on CD8
Identifiants
pubmed: 37593676
doi: 10.1080/2162402X.2023.2247303
pii: 2247303
pmc: PMC10431726
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2247303Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).
Références
Br J Cancer. 2021 May;124(10):1661-1669
pubmed: 33723392
Eur J Cancer. 2016 Jun;60:210-25
pubmed: 27084345
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
Int J Mol Sci. 2020 Mar 30;21(7):
pubmed: 32235439
Eur J Cancer. 2016 Jun;60:190-209
pubmed: 27085692
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Ann Oncol. 2017 Jun 01;28(6):1368-1379
pubmed: 28368458
JAMA Oncol. 2020 Apr 1;6(4):519-527
pubmed: 31895407
J Clin Oncol. 2020 Nov 20;38(33):3937-3946
pubmed: 32997575
Oncoimmunology. 2016 Nov 1;5(12):e1249559
pubmed: 28123888
Br J Cancer. 2018 May;118(10):1296-1301
pubmed: 29695768
Cancer Treat Rev. 2016 Mar;44:51-60
pubmed: 26874776
Nat Med. 2021 Aug;27(8):1432-1441
pubmed: 34239137
Semin Cancer Biol. 2020 Aug;64:29-35
pubmed: 30716481
Ann Rheum Dis. 2022 Aug 3;:
pubmed: 35922125
J Exp Clin Cancer Res. 2020 Dec 14;39(1):284
pubmed: 33317597
J Cell Mol Med. 2020 Dec;24(23):13703-13714
pubmed: 33094923
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
J Immunother. 2022 May 1;45(4):210-216
pubmed: 35250004
Exp Dermatol. 2023 Mar;32(3):240-249
pubmed: 36437644
Sci Rep. 2021 Apr 27;11(1):9029
pubmed: 33907229
Front Immunol. 2022 Apr 26;13:779691
pubmed: 35558065
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
Cancer Immunol Immunother. 2021 Aug;70(8):2209-2221
pubmed: 33481042
Nat Med. 2022 Feb;28(2):353-362
pubmed: 35027754
JAMA Oncol. 2019 Mar 1;5(3):376-383
pubmed: 30589930
Front Oncol. 2021 Feb 11;10:585311
pubmed: 33643899
Int J Cancer. 2015 May 15;136(10):2352-60
pubmed: 25353097
Clin Cancer Res. 2015 Dec 15;21(24):5453-9
pubmed: 26289067
Immunol Rev. 2017 Jul;278(1):87-100
pubmed: 28658550
Oncoimmunology. 2020 Feb 2;9(1):1722023
pubmed: 32076579
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Int J Mol Sci. 2021 Jul 27;22(15):
pubmed: 34360781
Front Immunol. 2023 Feb 13;14:1065767
pubmed: 36860876
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924
pubmed: 27698113
J Cancer Res Clin Oncol. 2021 Jun;147(6):1623-1630
pubmed: 33837821
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892846
Cancers (Basel). 2021 Apr 10;13(8):
pubmed: 33920288
Front Immunol. 2021 Sep 03;12:731947
pubmed: 34539668
J Cutan Pathol. 2019 Sep;46(9):627-636
pubmed: 30883858
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892835